

August 19th, 2021

Dear editor,

Please find attached files of revised manuscript in word format

**The effect of Shenyankangfu tablet treatment with adjuvant tacrolimus on idiopathic membranous nephropathy**

**Author:** Wei Lv<sup>1</sup>, Meirong Wang<sup>2</sup>, Chengzhen Zhang<sup>3</sup>, Xuexu Sun<sup>4</sup>, Zhenzhen Yan<sup>5</sup>, Xiaomin Hu<sup>6</sup>, Taotao Wang<sup>7</sup>

**Name of Journal:** World Journal of Clinical Cases

**Manuscript NO:** 68154

First of all, thank you for your careful guidance of this article. Revision has been made according to the suggestions of the reviewer:

**Reviewer:** 06129445

The incidence of idiopathic membranous nephropathy has continued to increase in recent years, and safe and effective treatments are of significant research interest. Cyclophosphamide is commonly used in idiopathic membranous nephropathy and can achieve certain therapeutic effects, but the incidence of adverse reactions is high. Tacrolimus is a new calcineurin inhibitor that can effectively improve renal function with low dose and high safety. In this study, the authors investigated the efficacy and safety of nephritis rehabilitation tablets combined with tacrolimus in the treatment of idiopathic membranous nephropathy. This study is designed well, and the results are interesting. After a minor revision, it can be accepted for publication. Comments: 1. Some minor language polishing should be corrected. 2. Tables should be edited. The "a" in the table 2 and table 3 should be noted and explained. 3. The limit of the study should be discussed.

Thank you for your advice.

After receiving the comments, we read the article in detail, corrected the language errors in the manuscript, noted and explained "a" and discussed the limit of the study Thank you again for publishing our manuscript in the World Journal of Clinical Cases.

Sincerely Yours,  
Taotao Wang